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Metabolic syndrome increases the risk of all-cause mortality, cardiovascular mortality and cardiovascular events in patients with
cardiovascular disease (CVD). This study assessed the predictors of metabolic syndrome, both its incidence and resolution in
a cohort of cardiac rehabilitation program graduates. Methods. A total of 154 and 80 participants without and with metabolic
syndromerespectivelywerefollowedfor48months.Anthropometricmeasurements,metabolicriskfactors,andqualityoflifewere
assessed at baseline and at 48 months. Logistic regression models were used to assess the predictors of metabolic syndrome onset
andresolution.Results.Increasingwaistcircumference(OR1.175,P ≤ 0.001)wasanindependentpredictorforincidentmetabolic
syndrome(R2 formodel =0.46).Increasingwaistcircumference (OR1.234, P ≤ 0.001),decreasingHDL-C(OR0.027, P = 0.005),
and increasing triglycerides (OR 3.005, P = 0.003) were predictors of metabolic syndrome resolution. Conclusion. Patients with
CVD that further develop metabolic syndrome are particularly susceptible for the cascade of cardiovascular events and mortality.
Increasing waist circumference confers a higher risk for future onset of metabolic syndrome in this group of patients. They will
require closer follow-up and should be targeted for further prevention strategies after cardiac rehabilitation program completion.
1.Introduction
The metabolic syndrome (MetS) is a prothrombotic, proin-
ﬂammatorystatecharacterizedbyabdominalobesity,insulin
resistance/hyperinsulinemia (leading to elevated plasma
glucose), elevated blood pressure (BP) and dyslipidemia
(high triglycerides, low-high-density lipoprotein [HDL-C]
with preponderance of small-dense, low-density lipoprotein
[LDL-C] particles) [1]. These metabolic changes are asso-
ciated with the development and progression of diabetes
and coronary artery disease [2, 3]. Previous studies have
reportedthatforpatientswithcardiovasculardisease(CVD),
MetS confers an even greater risk for cardiovascular events,
including cardiovascular and all-cause mortality than those
withoutMetS[4–7].Forexample,MetSriskestimatesforall-
causeandcardiovascularmortalitywerereportedtobegreat-
est in a population with existing CVD compared to those
without CVD (HR 1.47 versus 1.06, HR 2.53 versus 2.01,
P<0.05,resp.)[5].Likewise,thepresenceofMetSinwomen
with suspected coronary artery disease confers a signiﬁcantly
higher risk for cardiovascular events than in those with
normal metabolic status (HR 4.93 versus 1.41, P = 0.05)
[6]. As there is a synergistic eﬀect between MetS and CVD
oncardiovascularmorbidityandmortality[7],thesepatients
are at especially high risk, and it is therefore important to
identify MetS in patients with CVD as well as ﬁnd the best
predictors of it.
Cardiac rehabilitation programs (CRPs) are uniquely
positioned to assess the presence of MetS and are a proven
intervention in reducing CVD risk [8–10]. The purpose of
this study was to identify predictors of MetS in a cohort
of men and women with CVD free of MetS, over a four-
year period following completion of their CRP. We also
assessed predictors of MetS resolution in men and women
with both CVD and MetS over the same time period.
Speciﬁc attention was placed on identifying predictors that2 ISRN Cardiology
can be easily measured outside of the CRP environment and
readily available at the health care provider’s oﬃce without
substantial additional cost.
2. Methods
We used data from the Extensive Lifestyle Intervention
( E L M I )T r i a li nw h i c hat o t a lo f3 0 2m e na n dw o m e nw i t h
ischemic heart disease were recruited following completion
of a standard CRP for a four-year study [11]. The ELMI
Trial was a randomized study to test the eﬀectiveness
of a modest intervention of additional exercise sessions,
telephone follow-up, and risk factor and lifestyle counselling
compared to usual care. For the current analysis, the two
groups have been combined and analyzed together as there
were no diﬀerences between the two groups in outcomes
relevant to the current investigation.
The MetS was deﬁned according to the most recently
published harmonized criteria by the International Diabetes
Federation in conjunction with the National Heart, Lung,
and Blood Institute, American Heart Association, World
Heart Federation, International Atherosclerosis Society, and
International Association for the Study of Obesity [12].
Participants were classiﬁed as having MetS at CRP com-
pletion and at 48 months if they had three out of the
following ﬁve criteria: triglycerides ≥ 1.7mmol/L, HDL-
C < 1.00mmol/L for men and <1.30mmol/L for women
or speciﬁc treatment for these lipid abnormalities, BP ≥
130/85mmHg or speciﬁc treatment of diagnosed hyperten-
sion, fasting plasma glucose ≥ 5.6mmol/L, or previously
diagnosed diabetes [12]. The majority of participants in
the ELMI study were Caucasian; therefore, we chose the
waist circumference cut points for Europeans of ≥94cm for
men, ≥80cm for women. The cohort was retrospectively
assigned into the following categories at CRP completion:
(1) “New onset MetS” (participants who had no MetS at
baseline but had MetS at 48 months), (2) “MetS resolution”
(participants who had MetS at baseline but did not have
MetS at 48 months), (3) “Always MetS” (participants who
had MetS at baseline and 48 months), and (4) “Never
MetS” (participants who had no MetS at baseline and 48
months).
All participants underwent a baseline and a 48-month
assessment that consisted of cardiovascular risk factors
(lipid proﬁle, fasting blood glucose, and BP), lifestyle
(exercise capacity, leisurely exercise, and anthropometric
measurements) and psychosocial parameters (perceived
stress, illness intrusiveness, health-speciﬁc, and exercise self-
eﬃcacy). Body mass index (BMI) was calculated from
height (in metres) and weight (in kg) with participants
in street clothing and shoes removed. Waist circumference
was measured in cm at the point of maximal narrowing
of the trunk viewed from the anterior position with the
participant standing upright following a normal expiration
[13]. Systolic and diastolic BP were measured in mmHg and
assessed with a manual sphygmomanometer, recorded as the
average of two measures taken two minutes apart after ﬁve
minutes of seated rest. Fasting lipid proﬁle (total cholesterol
(TC), HDL-C, and triglycerides) and fasting blood glucose
were assessed using standard laboratory methodology [14].
CalculationofLDL-CwasdoneusingtheFriedwaldequation
[15]. Exercise capacity was determined by a symptom-
limited stress test and expressed in metabolic equivalents
(METS). Health-speciﬁc self-eﬃcacy was used to assess
the participant’s conﬁdence to achieve successful lifestyle
changes and was measured by a questionnaire based on the
Likert scoring [16]. Perceived stress and illness intrusiveness
were assessed through the Perceived Scale Rating [17]a n d
the Illness Intrusive Rating [18] based on the Likert scoring.
These questionnaires evaluate an individual’s perception of
stress in diﬀerent situations and the perception of how
their illness burden aﬀects diﬀerent aspects of their lives,
respectively.
3.StatisticalAnalysis
Baseline comparisons between the groups were done with
one-way ANOVA and Pearson’s chi square for continuous
and categorical variables, respectively. Multiple comparisons
were assessed with the Tukey correction for variables that
reached signiﬁcance. Paired sample t-tests were used to
compare risk factors at baseline and at 48 months within
each group. Multinomial logistic regression models were
used to assess for independent predictors of: (1) “New
onset MetS”, and (2) “MetS resolution.” Age and sex were
entered a priori. Variables were considered in the equation
according to their association with the MetS; therefore,
exercise variables such as baseline values of ﬁtness level in
metabolic equivalents, TC, LDL-C, triglycerides, HDL-C,
glucose, waist circumference and BP as well as psychosocial
parameters such as illness intrusiveness, perceived stress,
and health-speciﬁc self-eﬃcacy were considered. Group
assignment (intervention group versus usual care group),
was also entered as a variable in the equations; however,
as it was not a signiﬁcant contributor to our outcomes of
interest, it was not included in the ﬁnal models. Medication
intakeatbaselineforstatins,ACEinhibitors,calciumchannel
blockers, diabetes-related medications, and beta blockers
(taking the medication versus not taking the medication)
were also entered as variables in the equations; however, as
they were not predictive of our outcomes, they were not
included in the ﬁnal models. Variables were removed in a
backwards fashion according to their correlation to other
variables in the equation and their predictive value at each
step. As part of the model, special attention was placed on
those variables that can be easily assessed in the health care
provider’s oﬃce such as anthropometric measurements, BP
and psychosocial parameters such as illness intrusiveness,
perceived stress, and health-speciﬁc self-eﬃcacy. These vari-
ables were entered in the equation with age and sex, without
variables that needed laboratory measurements. This was
donetoaddressourpurposetoidentifypredictorsthatcanbe
measured in the health care provider’s oﬃce. These models
were based on 234 participants who had complete data. The
P value was set at 0.05. All data were analyzed using SPSS
version 18.ISRN Cardiology 3
4. Results
Of the 302 participants, 56 did not have outcome data at
48 months, and 12 had incomplete assessments. Those that
were lost to follow-up or had an incomplete assessment were
not signiﬁcantly diﬀerent from the participants included in
the present analysis (data not shown). This resulted in a
total of 234 participants who were retrospectively assigned as
follows: 121, 52, 28, and 33 participants in the “Never MetS,”
“Always MetS,” “MetS resolution” and “New onset MetS”
groups, respectively. Table 1 shows baseline comparisons of
demographic and cardiovascular risk factors between the
groups. There were no signiﬁcant diﬀerences in age, sex,
family history of CVD, coronary artery bypass graft or per-
cutaneous transluminal angiography, history of myocardial
infarction, TC, LDL-C, diastolic BP, exercise capacity, leisure
time physical activity, perceived stress, health-speciﬁc and
exercise self-eﬃcacy among the four groups. The “Never
MetS” group had a lower proportion of participants with
diabetes, lower waist circumference and BMI than the other
groups, as well as higher HDL-C and lower triglycerides
than the “Always MetS” and “MetS resolution” groups. The
“NeverMetS”grouphadlowerfastingbloodglucosethanthe
“Always MetS” group and lower illness intrusiveness than the
“MetS resolution” group. The “New onset MetS” group had
a lower proportion of participants with diabetes and lower
triglycerides than the “Always MetS” and “MetS resolution”
group, as well as higher HDL-C, lower BMI and lower waist
circumference than the “Always MetS” group. The “Always
MetS” group had a higher systolic BP than the “New onset
MetS” group.
Table 2 shows CVD risk factors at baseline and at 48
months for the four groups. The “Never MetS” group had
an increase in HDL-C, diastolic BP and waist circumference,
as well as a decrease in triglycerides, illness intrusiveness,
exercise capacity, and self-reported leisure time physical
activity (P ≤ 0.05). The “Always MetS” group had a decrease
inTC,perceivedstress,exercisecapacity,self-reportedleisure
time physical activity, and exercise self-eﬃcacy (P ≤ 0.05) as
well as an increase in waist circumference (P ≤ 0.05). The
“MetS resolution” group had a decrease in TC, triglycerides
and self-reported leisure time physical activity (P ≤ 0.01)
as well as an increase in HDL-C and exercise capacity (P ≤
0.05). The “New onset MetS” group had a decrease in HDL-
C, exercise capacity and exercise self-eﬃcacy an increase in
triglycerides, systolic and diastolic BP, and BMI and waist
circumference (P ≤ 0.05).
Table 3 outlines the results of the multinomial logistic
regression models to identify predictors for MetS onset at
48 months and MetS resolution at 48 months. All possible
baseline parameters were considered; waist circumference
was a signiﬁcant predictor of MetS onset (P ≤ 0.001, R2 =
0.46) after adjusting for age and sex. That is, an increase
in waist circumference was associated with an increase
in the risk of MetS. Model 2 shows the result of the
logistic regression model for independent predictors of MetS
resolutionat48months. Baselinewaistcircumference,HDL-
C and triglycerides were independent predictors of MetS
resolution after adjusting for age and sex (P ≤ 0.01, R2 =
0.59). This indicates that an increase in waist circumference
as well as an increase in triglycerides was associated with a
greater possibility of MetS resolution, while a decrease in
HDL-C was associated with a greater possibility of MetS
resolution.
5. Discussion
Our data show that increasing waist circumference was the
only signiﬁcant independent predictor of MetS after adjust-
ment for age and sex. Paradoxically, waist circumference
was also an independent predictor of MetS resolution as
well as decreasing HDL-C and increasing triglycerides after
adjustment for age and sex. An interesting ﬁnding was
that those participants that did not change their metabolic
status, the “Never MetS” group and the “Always MetS”
group, who represent the lowest and highest risk groups
respectively, experienced a deterioration of exercise capacity
and waist circumference during a four-year follow-up after
CRP completion.
Waist circumference has a strong association with the
metabolic syndrome cluster of abnormalities which in turn
strongly correlate with the development of CVD [19–
21]. In those with CVD, the concomitant existence of
the MetS cluster of abnormalities confers an even higher
risk for cardiovascular events, cardiovascular and all-cause
mortality [4–7]. Therefore, predicting the incidence of MetS
in individuals with CVD is important. Our ﬁndings show
that CRP graduates with an enlarged waist are at increased
risk of developing MetS in the next four years such that
for every 5cm increase in waist circumference the risk
of developing MetS in the next 48 months increased by
87.5%. Together, with age and sex, this model accounted
for 46% of the variation in new onset of MetS. Given that
waist circumference is a component of the MetS, it is not
unexpectedthatanenlargedwaistwouldpredictfutureonset
of MetS. However, it is important to note that none of
the other four components (triglycerides, HDL-C, fasting
glucose, or BP) were predictive.
The relation between waist circumference and the rest
of the parameters of the metabolic syndrome is well
documented; increasing values of waist circumference have
been associated with increasing triglyceride levels, fasting
insulin and glucose levels as well as decreasing HDL-C
levels in healthy middle-aged men and women [22]. Fox
et al. reported that waist circumference is highly correlated
with visceral adipose tissue in both men and women (r =
0.73 and 0.78, P ≤ 0.001, resp.) and, in turn, visceral
adipose tissue is highly correlated with HDL-C, systolic BP,
diastolic BP, and blood glucose [19]. Surprisingly, although
the measurement of waist in the clinical setting has increased
in the past 10 years, it is still under used in clinical practice
[23]. Identifying the risk for developing MetS amongst high-
risk patients is the next step to restratify this risk group.
Increased waist circumference was also positively associated
withagreaterresolutionofMetSinadditiontolowerHDL-C
and higher triglycerides levels at baseline. This might be4 ISRN Cardiology
Table 1: Baseline comparison of demographics and cardiovascular risk factors between “Never MetS”, “Always MetS”, “MetS new onset” and
“MetS resolution” groups.
Risk factors at baseline
Mean and SD and counts and percentages Overall
P value
Multiple
comparisons Never MetS
(n = 121)
Always MetS
(n = 52)
MetS resolution
(n = 28)
New onset
MetS (n = 33)
Age (years) 66.2 ±10.36 4 .5 ±8.36 5 .3 ±7.46 2 .9 ±7.7 0.295 —
Sex (male) 98 (81%) 41 (79%) 24 (86%) 29 (88%) 0.689 —
Family history of CVD 40 (33%) 16 (31%) 7 (25%) 15 (45%) 0.360 —
Coronary artery bypass
surgery 45 (37%) 20 (38%) 8 (29%) 10 (30%) 0.723 —
Percutaneous transluminal
coronary angiogram 47 (39%) 14 (27%) 12 (43%) 13 (39%) 0.401 —
Diabetes 8 (6%) 20 (38%) 9 (32%) 7 (21%) <0.001
<0.001
(0 / =1,2,3)
(3 / =1,2)
Previous myocardial
infarction 62 (51%) 24 (46%) 12 (43%) 23 (69%) 0.121 —
TC (mmol/L) 4.38 ±0.89 4.66 ±0.99 4.43 ±0.73 4.48 ±0.74 0.282 —
LDL-C (mmol/ L) 2.53 ±0.73 2.59 ±0.81 2.44 ±0.58 2.68 ±0.62 0.582 —
HDL-C (mmol/ L) 1.25 ±0.31 0.99 ±0.22 1.01 ±0.20 1.17 ±0.28 <0.001 <0.001 (0 / =1,2)
0.024 (1 / =3)
Triglycerides (mmol/ L) 1.32 ±0.66 2.37 ±0.84 2.15 ±1.11 1.38 ±0.50 <0.001 <0.001 (0 / =1,2)
<0.001 (3 / =1,2)
Fasting blood glucose
(mmol/L) 5.32 ±1.58 6.34 ±1.41 5.99 ±1.18 5.86 ±1.30 <0.001 <0.001 (0 / =1)
Systolic BP (mmHg) 126 ±22 134 ±17 130 ±27 120 ±14 0.024 0.020 (1 / =3)
Diastolic BP (mmHg) 71 ±10 75 ±10 72 ±13 73 ±10 0.154 —
Body mass index (kg/m2)2 5 .4 ±2.93 0 .4 ±4.22 8 .6 ±3.92 7 .6 ±3.1 <0.001
<0.001
(0 / =1,2,3)
<0.002 (1 / =3)
Waist circumference (cm) 86.7 ±9.0 102.4 ±11.59 9 .8 ±11.09 5 .6 ±9.1 <0.001
<0.001
(0 / =1,2,3)
0.013 (1 / =3)
Exercise capacity (METS) 10.8 ±4.49 .1 ±2.21 3 .8 ±2.91 0 .7 ±2.3 0.109 —
Leisure time physical
activity (kcal/week) 3029 ±337 2837 ±1708 3090 ±558 3219 ±226 0.894 —
Perceived stress 32 ±83 1 ±83 4 ±93 2 ±6 0.512 —
Illness intrusiveness 27 ±11 33 ±16 36 ±19 28 ±13 0.020 0.040 (0 / =2)
Health-speciﬁc self-eﬃcacy 43 ±44 2 ±44 2 ±64 1 ±4 0.064 —
Exercise self-eﬃcacy 67 ±12 70 ±10 63 ±13 64 ±12 0.080 —
CVD: cardiovascular disease, TC: total cholesterol, LDL-C: low density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol.
One-way ANOVA and Pearson’s chi square for continuous and categorical variables, respectively. Multiple comparisons were assessed with the Tukey
correction. Multiple comparisons: 0: Never MetS, 1: Always MetS, 2: MetS resolution, 3: New onset MetS.
Note: 0 / =1 means that Never MetS is signiﬁcantly diﬀerent with Always MetS group.
explained in part by the patient’s higher drive to improve
their risk factor proﬁle by a perception of a higher degree
of disease burden. However, given that we did not observe
improvements in anthropometric measurements, exercise
capacity or psychosocial variables, which would be reﬂective
of changes in lifestyle, it is possible that the higher-risk factor
levels may have resulted in the patients being more readily
identiﬁed for pharmacological treatment, with a higher
proportion of high-risk patients being on lipid-lowering
medications(datanotshown).Thisisreﬂectedbytheﬁnding
that the “MetS resolution” group experienced improvements
of TC, HDL-C, and triglycerides without any improvement
in waist circumference. It is important to mention that
having an enlarged waist at CRP completion and a decreased
waist at 48 months is what deﬁned the “MetS resolution”
group; therefore, it is not surprising to ﬁnd that waist
circumference was associated with MetS resolution. The fact
that an increased waist circumference was also associatedISRN Cardiology 5
Table 2: CVD risk factors at baseline and at 48 months for “Never MetS,” “Always MetS,” “MetS new onset” and “MetS resolution” groups.
CVD risk factors
Never MetS (n = 121) Always MetS (n = 52) MetS resolution (n = 28) New Onset MetS (n = 33)
Baseline 48 months Baseline 48 months Baseline 48 months Baseline 48 months
TC (mmol/L) 4.39 ±0.90 4.32 ±0.90 4.67 ±0.99 4.40 ±0.95
‡ 4.43 ±0.73 4.07 ±0.77
‡ 4.51 ±0.74 4.55 ±0.83
LDL-C (mmol/L) 2.52 ±0.74 2.48 ±0.76 2.57 ±0.80 2.41 ±0.69 2.45 ±0.59 2.29 ±0.66 2.71 ±0.62 2.64 ±0.71
HDL-C (mmol/L) 1.24 ±0.30 1.30 ±0.36
† 0.99 ±0.22 0.98 ±0.21 1.01 ±0.20 1.18 ±0.26
† 1.17 ±0.28 1.09 ±0.27
§
Triglycerides (mmol/L) 1.32 ±0.67 1.18 ±0.60
‡ 2.37 ±0.85 2.34 ±2.20 2.16 ±1.11 1.30 ±0.50
∗ 1.38 ±0.51 1.79 ±0.84
†
Fasting blood glucose
(mmol/L) 5.3 ±1.65 .3 ±0.86 .33 ±1.42 6.67 ±1.47 5.9 ±1.25 .6 ±0.75 .7 ±1.26 .2 ±1.4
Systolic BP (mmHg) 126 ±21 127 ±21 134 ±17 134 ±17 130 ±27 122 ±17 120 ±14 131 ±14
†
Diastolic BP (mmHg) 71 ±10 74 ±12
† 75 ±10 77 ±97 2 ±13 71 ±97 3 ±10 79 ±10
†
Body mass index
(kg/m2) 25.4 ±2.92 5 .6 ±3.53 0 .4 ±4.23 0 .7 ±4.52 8 .6 ±3.82 8 .3 ±4.52 7 .6 ±3.02 9 .1 ±3.7
∗
Waist circumference
(cm) 86.7 ±8.98 8 .6 ±10.9
∗ 102.4 ±11.5 104.7 ±12.8
‡ 99.8 ±11.19 9 .0 ±12.29 5 .6 ±9.1 100.9 ±10.9
∗
Exercise capacity
(METs) 10.6 ±2.41 0 .0 ±2.7
† 9.5 ±2.18 .9 ±2.3
† 14.8 ±22.51 7 .4 ±36.81 0 .6 ±2.31 0 .1 ±2.4
‡
Leisure time physical
activity (kcal/week) 2985 ±2225 2230 ±1828
∗ 2773 ±1616 2247 ±2104
‡ 3066 ±1538 1786±1042
† 2784 ±19778 2198 ±3011
Perceived stress 32 ±73 2 ±83 2 ±83 1 ±83 4 ±93 3 ±10 33 ±63 1 ±5
Illness intrusiveness 27 ±11 24 ±11
‡ 33 ±14 30 ±14 35 ±19 31 ±16 28 ±15 27 ±15
Health-speciﬁc
self-eﬃcacy 43 ±44 3 ±44 2 ±44 2 ±44 2 ±54 2 ±44 1 ±44 0 ±4
Exercise self-eﬃcacy 67 ±12 64 ±14 70 ±10 63 ± 15
∗ 65 ±11 58 ±16 64 ±13 58 ±14
‡
∗P ≤ 0.001.
†P ≤ 0.01.
‡P ≤ 0.05.
Paired sample t-tests.
Total cholesterol, LDL-C: low density lipoprotein cholesterol, HDL-C: high density lipoprotein cholesterol, and BP: blood pressure.
with MetS onset over 48 months indicates the importance of
managing these patients eﬀectively whether through lifestyle
changes orpharmaco therapy to reduce their future risk of
CVD.
While not directly associated with our primary question,
an interesting ﬁnding was that patients in either the “Never
MetS” or “Always MetS” had a decrease in exercise capacity
and an increase in waist circumference. This is comparable
to the general CRP population, where it has been reported
that adherence to favourable lifestyle behaviours decrease
shortly after CRP completion [24]. This may reﬂect the
challenges that both, the patients and the physicians have
to successfully manage cardiovascular risk factors through
behavioural changes [25–27]. Lifestyle changes are essential
in the management and prevention of the MetS [28],
and associated complications such as diabetes [29]a n d
cardiovascular events [30]. The “New onset MetS” group
had an increase in BP, anthropometric measurements and
triglycerides and a decrease in HDL-C, exercise capacity and
exercise self-eﬃcacy. Furthermore, the highest risk group,
“AlwaysMetS,”aswellasthelowestriskgroup,“NeverMetS,”
experienced both an increase in waist circumference and a
decrease in exercise capacity, which in turn reﬂects deterio-
rationoflifestylebehaviours.Theimportanceofmaintaining
healthylifestylebehavioursisvastlydocumented.Myersetal.
reported that an improvement of 1MET in exercise capacity
(deﬁned as 3.5mL O2/Kg/min) provides a 12% reduction
in all-cause mortality in healthy men [30] ,a n da n1 8 %
reduction in all-cause mortality in men with diabetes [31].
Our results highlight the failure of most patients to maintain
positive behavioural changes, even after a CRP. This is an
important caveat that needs to be addressed in order to
prevent the appearance of MetS in patients with CVD and
in the long-term management of patients after CRP.
6. Study Limitations
As the groups were retrospectively assigned, we cannot
exclude the possibility of a bias in the group assignment.
Also the ELMI Trial was not designed to prospectively assess
incident MetS. However, our ﬁndings, supported by the
results of previous studies do suggest that the assessment
of waist circumference in a high-risk population can help
physicians identify those at greatest risk. We must also
acknowledge that our study population, namely, patients
completing a CRP, may not be representative of the general
population of CVD patients. However, we have no reason to
believe that waist circumference would be any less important
in patients not attending a CRP. Lastly, we assessed the
predictors of MetS resolution and incidence in a cohort
primarily of European descent, and our results may not be
applicable to other ethnic groups.6 ISRN Cardiology
Table 3:Multinomialregressionmodelsforindependentpredictors
of “New onset MetS” 48 months (Model 1) and for independent
predictors of “MetS Resolution” (Model 2) following cardiac reha-
bilitation.
Variables
Model 1 (R2 = 0.46)
P value
Odds ratio 95% conﬁdence
interval
Age (years) 0.971 0.927–1.018 0.220
Sex 0.187 0.043–0.823 0.027
Waist
circumference
(cm)
1.175 1.102–1.253 ≤0.001
Model 2 (R2 = 0.59)
Age (years) 1.027 0.966–1.092 0.396
Sex 0.030 0.004–0.202 ≤0.001
Waist
circumference
(cm)
1.234 1.145–1.330 ≤0.001
HDL-C (mmol/L) 0.027 0.002–0.344 0.005
Triglycerides
(mmol/L) 3.005 1.465–6.166 0.003
Multinomial logistic regression models.
7. Conclusion
Over a four-year follow-up period, an increasing waist
circumference is the only independent predictor of future
MetS in patients with CVD. Likewise, an increasing waist
was also a predictor of MetS resolution, as were increasing
triglyceride levels and decreasing HDL-C. These ﬁndings
strengthen the notion that patients with CVD with an
enlarged waist at CRP completion are at risk of further
cardiometabolic deterioration. Our results highlight the
clinical importance of waist circumference for identifying
and restratifying high-risk patients. Waist measurement is
readily available to identify individuals at the highest risk—
those with CVD at risk of future MetS. A cautionary note
is that patients who did not have MetS at baseline or at 48
months still experienced an increase in waist circumference
and a decrease in exercise capacity. This also occurred in
patients with the MetS at baseline who still met the criteria
at 48 months, indicating that both the lowest and highest
risk patients are susceptible to those adverse changes and
need to be regularly assessed and appropriately managed.
Traditionally, the MetS has been used to assess the risk
of future CVD and diabetes, whereas our study has the
strength of considering the MetS and its synergistic eﬀect
with CVD as an endpoint that confers high cardiometabolic
risk, and therefore, should be prevented. Our data show
that waist circumference is a predictor of both, MetS onset
and resolution; therefore, those patients with CVD and an
enlarged waist need further risk factor management and
follow-up. These results provide further data on patients
with CVD at risk of MetS. An extension of CRP and/or
acloser follow-up after CRP completion for patients with
CVD and an enlarged waist would be a practical intervention
that may improve quality of care.
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